These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8135853)
1. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line. Shellard SA; Hosking LK; Hill BT Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853 [TBL] [Abstract][Full Text] [Related]
2. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098 [TBL] [Abstract][Full Text] [Related]
3. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. Hosking LK; Whelan RD; Shellard SA; Davies SL; Hickson ID; Danks MK; Hill BT Int J Cancer; 1994 Apr; 57(2):259-67. PubMed ID: 7908897 [TBL] [Abstract][Full Text] [Related]
4. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457 [TBL] [Abstract][Full Text] [Related]
5. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Taverna P; Hansson J; Scanlon KJ; Hill BT Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602 [TBL] [Abstract][Full Text] [Related]
6. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688 [TBL] [Abstract][Full Text] [Related]
8. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Bedford P; Fichtinger-Schepman AM; Shellard SA; Walker MC; Masters JR; Hill BT Cancer Res; 1988 Jun; 48(11):3019-24. PubMed ID: 3365691 [TBL] [Abstract][Full Text] [Related]
9. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Shellard SA; Hosking LK; Hill BT Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800 [TBL] [Abstract][Full Text] [Related]
10. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA. Maynard KR; Hosking LK; Hill BT Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540 [TBL] [Abstract][Full Text] [Related]
11. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines. Lock RB; Hill BT Int J Cancer; 1988 Sep; 42(3):373-81. PubMed ID: 3417366 [TBL] [Abstract][Full Text] [Related]
12. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112 [TBL] [Abstract][Full Text] [Related]
13. Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Whelan RD; Hosking LK; Townsend AJ; Cowan KH; Hill BT Cancer Commun; 1989; 1(6):359-65. PubMed ID: 2702041 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin. Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries EG; D'Incalci M Eur J Cancer; 1996 Oct; 32A(11):2011-8. PubMed ID: 8943689 [TBL] [Abstract][Full Text] [Related]
16. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754 [TBL] [Abstract][Full Text] [Related]
17. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Johnson SW; Shen D; Pastan I; Gottesman MM; Hamilton TC Exp Cell Res; 1996 Jul; 226(1):133-9. PubMed ID: 8660948 [TBL] [Abstract][Full Text] [Related]
18. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534 [TBL] [Abstract][Full Text] [Related]
19. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Oldenburg J; Begg AC; van Vugt MJ; Ruevekamp M; Schornagel JH; Pinedo HM; Los G Cancer Res; 1994 Jan; 54(2):487-93. PubMed ID: 8275486 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N; Lam YM; Pym J; Campling BG Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]